Amgen, Inc, One Amgen Center Drive, Mailstop D2262, Thousand Oaks, CA, 91320, USA.
Adelphi Research, Doylestown, PA, USA.
Support Care Cancer. 2021 Nov;29(11):6731-6740. doi: 10.1007/s00520-021-06134-8. Epub 2021 May 11.
To understand the extent to which metastatic colorectal cancer (mCRC) patients receive education on the prevention and management associated with skin rash following Vectibix treatment. Furthermore, to investigate how this adverse event affects a patient's quality of life (QoL) and influences their treatment decisions.
A cross-sectional survey was administered to 200 mCRC patients (100 Vectibix users and 100 Vectibix non-users). After excluding respondents who had used cetuximab, 61 Vectibix users and 56 Vectibix non-users remained.
Most Vectibix users (79%) experienced a skin rash in response to treatment of which 65% considered the rash moderate, 27% mild, and 8% severe. Vectibix users generally felt they were adequately informed about the rash (83%), with the most common messages received related to sun protection. However, sunscreen was used by only 42% of patients prior to rash and 60% of patients following the appearance of rash. The use of oral antibiotics was low prior to rash (21%) and following rash (46%). Among patients experiencing a rash within the past week (n=16), 75% reported the rash had a large negative impact on their QoL based on the Dermatology Life Quality Index.
There was a disconnect between patients feeling they were adequately informed and use of prevention and management strategies such as sun protection. This suggests a gap in patient education and adoption currently exists on management strategies both prior to and following the appearance of rash. Given the negative impact that skin toxicity has on the patient's quality of life, it is essential that patients receive and subsequently utilize all information that can minimize rash severity.
了解转移性结直肠癌（mCRC）患者在接受 Vectibix 治疗后，在皮疹预防和管理方面接受教育的程度。此外，还调查了这种不良反应如何影响患者的生活质量（QoL），并影响他们的治疗决策。
对 200 名 mCRC 患者（100 名 Vectibix 使用者和 100 名 Vectibix 非使用者）进行了横断面调查。在排除了使用西妥昔单抗的患者后，仍有 61 名 Vectibix 使用者和 56 名 Vectibix 非使用者。
大多数 Vectibix 使用者（79%）在治疗中出现皮疹，其中 65%认为皮疹为中度，27%为轻度，8%为重度。Vectibix 使用者普遍认为他们对皮疹有足够的了解（83%），最常见的信息与防晒有关。然而，只有 42%的患者在出现皮疹前使用防晒霜，60%的患者在出现皮疹后使用防晒霜。在出现皮疹前（21%）和出现皮疹后（46%），使用口服抗生素的情况较低。在过去一周内出现皮疹的患者中（n=16），75%的患者根据皮肤病生活质量指数报告皮疹对他们的 QoL 有很大的负面影响。
患者感觉自己得到了充分的信息，但在预防和管理策略的使用上存在脱节，例如防晒。这表明在皮疹出现之前和之后，患者的教育和管理策略的采用都存在差距。鉴于皮肤毒性对患者生活质量的负面影响，患者必须接受并随后利用所有可以最小化皮疹严重程度的信息。
